FDA Alerts

The FDA approved osimertinib for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.

The FDA approved Ocrevus for the treatment of relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adult patients.

The US Food and Drug Administration has approved Dupixent for the treatment of moderate-to-severe eczema in adults.

The FDA has approved Xadago, an add-on treatment for patients with Parkinson disease who experience “off” episodes.

The FDA approved ribociclib, taken with an aromatase inhibitor, for the treatment of advanced or metastatic breast cancer in post-menopause women.

The FDA has approved Noctiva (desmopressin acetate) nasal spray for the treatment of frequent nighttime urination due to the overproduction of urine.

The US Food and Drug Administration has approved Odactra for the treatment of house dust mite-induced nasal inflammation.

The FDA has approved Xermelo to be used in combination with somatostatin analogue therapy for the treatment of carcinoid syndrome diarrhea.

The FDA has approved once-daily Qtern for the treatment of patients with type 2 diabetes, as an adjunct to diet and exercise for the improvement of glycemic control.